Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 19;23(3):1063. doi: 10.3390/ijms23031063

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

The effects of JG-231 on TT and MZ-CRC-1 xenografts in mice. (A) Changes in tumor sizes in athymic mice bearing TT or MZ-CRC-1 xenografts. JG-231 (4 mg/kg/dose) dissolved in 200 μL vehicle was administered intraperitoneally every other day for the indicated treatment period, beginning from day 22 (TT) and day 32 (MZ-CRC-1) after tumor implantation. The control group was treated with the vehicle only. (B) Tumor growth rates in (A) determined by calculating the rate-based T/C ratios. (C) Tumor weights at the time of sacrifice in (A). (D) Animal body weight changes in (A). Data in (A,D) are mean ± SEM. Horizontal dotted lines and vertical lines in (B,C) indicate means and 95% Confidence Intervals, respectively. Data are from a single cohort of 4 to 7 mice per treatment group (TT, 4 mice for vehicle, 4 mice for JG-231; MZ-CRC-1, 7 mice for vehicle, 5 mice for JG-231). Each mouse developed one tumor. * p < 0.05, ** p < 0.01, *** p < 0.001 (A,D, two-way ANOVA with Bonferroni post-tests; (B,C), two-tailed t-tests).

The effects of JG-231 on TT and MZ-CRC-1 xenografts in mice. (A) Changes in tumor sizes in athymic mice bearing TT or MZ-CRC-1 xenografts. JG-231 (4 mg/kg/dose) dissolved in 200 μL vehicle was administered intraperitoneally every other day for the indicated treatment period, beginning from day 22 (TT) and day 32 (MZ-CRC-1) after tumor implantation. The control group was treated with the vehicle only. (B) Tumor growth rates in (A) determined by calculating the rate-based T/C ratios. (C) Tumor weights at the time of sacrifice in (A). (D) Animal body weight changes in (A). Data in (A,D) are mean ± SEM. Horizontal dotted lines and vertical lines in (B,C) indicate means and 95% Confidence Intervals, respectively. Data are from a single cohort of 4 to 7 mice per treatment group (TT, 4 mice for vehicle, 4 mice for JG-231; MZ-CRC-1, 7 mice for vehicle, 5 mice for JG-231). Each mouse developed one tumor. * p < 0.05, ** p < 0.01, *** p < 0.001 (A,D, two-way ANOVA with Bonferroni post-tests; (B,C), two-tailed t-tests).